1. Home
  2. ALGS vs NNVC Comparison

ALGS vs NNVC Comparison

Compare ALGS & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aligos Therapeutics Inc.

ALGS

Aligos Therapeutics Inc.

HOLD

Current Price

$5.57

Market Cap

34.6M

Sector

Health Care

ML Signal

HOLD

NNVC

NanoViricides Inc.

HOLD

Current Price

$1.74

Market Cap

35.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALGS
NNVC
Founded
2018
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.6M
35.2M
IPO Year
2020
2008

Fundamental Metrics

Financial Performance
Metric
ALGS
NNVC
Price
$5.57
$1.74
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$39.33
N/A
AVG Volume (30 Days)
48.7K
485.0K
Earning Date
05-05-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
88.30
10.00
EPS
N/A
N/A
Revenue
$2,186,000.00
N/A
Revenue This Year
$32.20
N/A
Revenue Next Year
$4.71
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.98
$0.85
52 Week High
$13.69
$2.23

Technical Indicators

Market Signals
Indicator
ALGS
NNVC
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
ALGS
NNVC

About ALGS Aligos Therapeutics Inc.

Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.

About NNVC NanoViricides Inc.

Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

Share on Social Networks: